RxSight, Inc. Investors: Company Investigated by the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their losses​

LOS ANGELES, July 23, 2025 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises RxSight, Inc. (“RxSight” or “the Company”) (NASDAQ: RXST) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. RxSight investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

CASE ALLEGATIONS: RxSight is a commercial-stage medical technology company specializing in the development, manufacturing, and commercialization of light adjustable intraocular lenses (LALs), which are used in cataract surgery.

According to the class action lawsuit, throughout the Class Period, RxSight and its executives made materially false and/or misleading statements and/or failed to disclose critical information, including that:

1. The company was experiencing adoption challenges and underlying structural issues that were negatively impacting sales and product utilization;
2. RxSight had overstated market demand for its products; and
3. As a result, the company was unlikely to meet its previously issued financial guidance for fiscal year 2025.

The lawsuit further alleges that on July 8, 2025, RxSight issued its preliminary Q2 2025 financial results, revealing significant declines in sales of its Light Delivery Devices (LDDs), reduced LAL utilization, and lower overall revenue. In addition, RxSight revised its full-year 2025 revenue guidance downward by approximately $42.5 million at the midpoint. During the corresponding investor communication, RxSight’s CEO, Ronald Kurtz, acknowledged that “adoption challenges over the last few quarters have been a primary reason for the LDD stall.”

Following this disclosure, shares of RxSight declined by nearly 38%, according to the complaint.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bars
[email protected]
310-692-8883
www.portnoylaw.com

Attorney Advertising

Wall St Business News, Latest and Up-to-date Business Stories from Newsmakers of Tomorrow